Valneva SE (VALN)
NASDAQ: VALN · IEX Real-Time Price · USD
7.71
+0.37 (5.04%)
At close: May 3, 2024, 3:57 PM
7.50
-0.21 (-2.79%)
After-hours: May 3, 2024, 5:30 PM EDT
Valneva SE Revenue
In the year 2023, Valneva SE had annual revenue of $170.79M, a decrease of -55.57%. Revenue in the quarter ending December 31, 2023 was $46.55M, a -60.72% decrease year-over-year.
Revenue (ttm)
$170.79M
Revenue Growth
-55.57%
P/S Ratio
3.14
Revenue / Employee
$252,651
Employees
676
Market Cap
536.43M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 170.79M | -213.57M | -55.57% |
Dec 31, 2022 | 384.36M | -11.19M | -2.83% |
Dec 31, 2021 | 395.55M | 261.01M | 194.01% |
Dec 31, 2020 | 134.54M | -7.26M | -5.12% |
Dec 31, 2019 | 141.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Talkspace | 150.05M |
Avid Bioservices | 136.74M |
Alector | 97.06M |
UroGen Pharma | 82.71M |
Shattuck Labs | 2.72M |
VALN News
- 5 weeks ago - Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate - GlobeNewsWire
- 5 weeks ago - Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F - GlobeNewsWire
- 6 weeks ago - Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. - GlobeNewsWire
- 6 weeks ago - French biotech company Valneva raises product sales guidance - Reuters
- 6 weeks ago - Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook - GlobeNewsWire
- 6 weeks ago - Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed - GlobeNewsWire
- 2 months ago - Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences - GlobeNewsWire
- 2 months ago - U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ® - GlobeNewsWire